Tumor-associated macrophages in nanomaterial-based anti-tumor therapy: as target spots or delivery platforms
暂无分享,去创建一个
Qiang Zhang | Jiantong Sun | Ling He | Jinting Jiang | Jixuan Zheng | Yicheng Pu | T. Xu | Xiao Liang | Jixuan Zheng
[1] Zhijun Sun,et al. LIMP-2 enhances cancer stem-like cell properties by promoting autophagy-induced GSK3β degradation in head and neck squamous cell carcinoma , 2023, International Journal of Oral Science.
[2] J. Nör,et al. Therapeutic inhibition of Bmi-1 ablates chemoresistant cancer stem cells in adenoid cystic carcinoma. , 2023, Oral oncology.
[3] Jin-Xiu Liu,et al. Barrier permeation and improved nanomedicine delivery in tumor microenvironments. , 2023, Cancer letters.
[4] X. Liu,et al. Injectable Scaffolds for In Vivo Programmed Macrophages Manufacture and Postoperative Cancer Immunotherapy , 2023, Advanced Functional Materials.
[5] Yun Zhang,et al. Rhodiola rosea polysaccharides-based nanoparticles loaded with DOX boosts chemo-immunotherapy for triple-negative breast cancer by re-educating tumor-associated macrophages. , 2023, International journal of biological macromolecules.
[6] C. O’Driscoll,et al. Sialic Acid-Targeted Cyclodextrin-Based Nanoparticles Deliver CSF-1R siRNA and Reprogram Tumour-Associated Macrophages for Immunotherapy of Prostate Cancer. , 2023, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[7] R. Weissleder,et al. T cell-independent eradication of experimental glioma by intravenous TLR7/8-agonist-loaded nanoparticles , 2023, Nature Communications.
[8] Wuliang Wang,et al. Identification of stemness subtypes and features to improve endometrial cancer treatment using machine learning. , 2023, Artificial cells, nanomedicine, and biotechnology.
[9] Quanyin Hu,et al. Chemically engineering cells for precision medicine. , 2023, Chemical Society reviews.
[10] M. Zhang,et al. Overcoming pancreatic cancer immune resistance by codelivery of CCR2 antagonist using a STING-activating gemcitabine-based nanocarrier. , 2022, Materials today.
[11] Jiesi Luo,et al. Macrophage cell membrane-based nanoparticles: a new promising biomimetic platform for targeted delivery and treatment , 2022, Journal of Nanobiotechnology.
[12] Soyoung Kim,et al. Enhanced Therapeutic Effect of Optimized Melittin-dKLA, a Peptide Agent Targeting M2-like Tumor-Associated Macrophages in Triple-Negative Breast Cancer , 2022, International journal of molecular sciences.
[13] Saji Uthaman,et al. Light and immunostimulant mediated in situ re-education of tumor-associated macrophages using photosensitizer conjugated mannan nanoparticles for boosting immuno-photodynamic anti-metastasis therapy. , 2022, Biomaterials Science.
[14] A. Mikaelyan,et al. Macrophage In Vitro and In Vivo Tracking via Anchored Microcapsules. , 2022, ACS applied materials & interfaces.
[15] Wentong Li,et al. Leveraging Nanodrug Delivery System for Simultaneously Targeting Tumor Cells and M2 Tumor-Associated Macrophages for Efficient Colon Cancer Therapy. , 2022, ACS applied materials & interfaces.
[16] R. Weichselbaum,et al. Zinc cyclic di-AMP nanoparticles target and suppress tumours via endothelial STING activation and tumour-associated macrophage reinvigoration , 2022, Nature nanotechnology.
[17] H. Gu,et al. Mannose and Hyaluronic Acid Dual-Modified Iron Oxide Enhances Neoantigen-Based Peptide Vaccine Therapy by Polarizing Tumor-Associated Macrophages , 2022, Cancers.
[18] I. Joni,et al. Monoclonal antibody as a targeting mediator for nanoparticle targeted delivery system for lung cancer , 2022, Drug delivery.
[19] Xu Chen,et al. Bidirectional anisotropic palladium nanozymes reprogram macrophages to enhance collaborative chemodynamic therapy of colorectal cancer. , 2022, Acta biomaterialia.
[20] T. C. Elebiyo,et al. Reassessing vascular endothelial growth factor (VEGF) in anti-angiogenic cancer therapy. , 2022, Cancer treatment and research communications.
[21] J. Kim,et al. Tumor-associated macrophage-targeted photodynamic cancer therapy using a dextran sulfate-based nano-photosensitizer. , 2022, International journal of biological macromolecules.
[22] Liangliang Xu,et al. Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors , 2022, Journal of Hematology & Oncology.
[23] Michael R Hamblin,et al. Macrophage Cell Membrane‐Cloaked Nanoplatforms for Biomedical Applications , 2022, Small methods.
[24] T. Xia,et al. Silver nanoclusters show advantages in macrophage tracing in vivo and modulation of anti-tumor immuno-microenvironment. , 2022, Journal of controlled release : official journal of the Controlled Release Society.
[25] T. Teesalu,et al. Depletion of Mannose Receptor–Positive Tumor-associated Macrophages via a Peptide-targeted Star-shaped Polyglutamate Inhibits Breast Cancer Progression in Mice , 2022, Cancer research communications.
[26] Lijun Yang,et al. Phosphoinositide 3-kinase/Akt and its related signaling pathways in the regulation of tumor-associated macrophages polarization , 2022, Molecular and Cellular Biochemistry.
[27] Hebao Yuan,et al. Albumin nanoparticle containing a PI3Kγ inhibitor and paclitaxel in combination with α-PD1 induces tumor remission of breast cancer in mice , 2022, Science Translational Medicine.
[28] W. Chan,et al. Macrophages Actively Transport Nanoparticles in Tumors After Extravasation. , 2022, ACS nano.
[29] Quanyin Hu,et al. Depletion of tumor associated macrophages enhances local and systemic platelet-mediated anti-PD-1 delivery for post-surgery tumor recurrence treatment , 2022, Nature Communications.
[30] R. Brekken,et al. Are TEMs Canceled? Questioning the Functional Relevance of Tie2-Expressing Macrophages. , 2022, Cancer research.
[31] Zhirong Zhang,et al. Dual-Targeting of Tumor Cells and Tumor-Associated Macrophages by Palmitic Acid Modified Albumin Nanoparticles for Antitumor and Antimetastasis Therapy. , 2022, ACS applied materials & interfaces.
[32] A. Borowsky,et al. Magnetic resonance imaging of tumor-associated-macrophages (TAMs) with a nanoparticle contrast agent , 2022, RSC advances.
[33] P. Delputte,et al. Targeting of sialoadhesin-expressing macrophages through antibody-conjugated (polyethylene glycol) poly(lactic-co-glycolic acid) nanoparticles , 2022, Journal of Nanoparticle Research.
[34] Tingting Wu,et al. Engineering Macrophage Exosome Disguised Biodegradable Nanoplatform for Enhanced Sonodynamic Therapy of Glioblastoma , 2022, Advanced materials.
[35] M. Chu,et al. Macrophage membrane coated nanoparticles: a biomimetic approach for enhanced and targeted delivery. , 2022, Biomaterials science.
[36] E. Vasile,et al. Macrophage-targeted mannose-decorated PLGA-vegetable oil hybrid nanoparticles loaded with anti-inflammatory agents. , 2022, Colloids and surfaces. B, Biointerfaces.
[37] Ke Gong,et al. Exosome-liposome hybrid nanoparticle codelivery of TP and miR497 conspicuously overcomes chemoresistant ovarian cancer , 2022, Journal of Nanobiotechnology.
[38] Dunwan Zhu,et al. Design of Light‐Activated Nanoplatform through Boosting “Eat Me” Signals for Improved CD47‐Blocking Immunotherapy , 2022, Advanced healthcare materials.
[39] D. Roy,et al. Arming Immune Cell Therapeutics with Polymeric Prodrugs , 2021, Advanced Healthcare Materials.
[40] H. Gu,et al. Emerging Nanoparticle Strategies for Modulating Tumor-Associated Macrophage Polarization , 2021, Biomolecules.
[41] Dongjuan Yang,et al. Biodegradable mesoporous nanocomposites with dual-targeting function for enhanced anti-tumor therapy. , 2021, Journal of controlled release : official journal of the Controlled Release Society.
[42] Xin Huang,et al. Artificial exosomes mediated spatiotemporal-resolved and targeted delivery of epigenetic inhibitors , 2021, Journal of Nanobiotechnology.
[43] Yazhou Wang,et al. Biomimetic neutrophil and macrophage dual membrane-coated nanoplatform with orchestrated tumor-microenvironment responsive capability promotes therapeutic efficacy against glioma , 2021, Chemical Engineering Journal.
[44] Y. Liu,et al. Tumor associated macrophage and microbe: the potential targets of tumor vaccine delivery. , 2021, Advanced drug delivery reviews.
[45] Xiangliang Yang,et al. Engineered Iron-Based Nanoplatform Amplifies Repolarization of M2-Like Tumor-Associated Macrophages for Enhanced Cancer Immunotherapy , 2021, Chemical Engineering Journal.
[46] M. Amiji,et al. Hyaluronic acid nanoparticles encapsulated microRNA-125b repolarizes tumor-associated macrophages in pancreatic cancer. , 2021, Nanomedicine.
[47] M. Piris. SPARC macrophages in lymphoma. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.
[48] P. Mäser,et al. From Magic Bullet to Magic Bomb: Reductive Bioactivation of Antiparasitic Agents. , 2021, ACS infectious diseases.
[49] C. Fernandez,et al. Engineering a folic acid-decorated ultrasmall gemcitabine nanocarrier for breast cancer therapy: Dual targeting of tumor cells and tumor-associated macrophages , 2021, Acta pharmaceutica Sinica. B.
[50] Jinhua Zhang,et al. Tumor-Associated Macrophages (TAMs) in Colorectal Cancer (CRC): From Mechanism to Therapy and Prognosis , 2021, International journal of molecular sciences.
[51] X. Mou,et al. Mitochondria-targeted and ultrasound-responsive nanoparticles for oxygen and nitric oxide codelivery to reverse immunosuppression and enhance sonodynamic therapy for immune activation , 2021, Theranostics.
[52] Si-Yang Song,et al. Tumor Associated Macrophages and TAMs‐Based Anti‐Tumor Nanomedicines , 2021, Advanced healthcare materials.
[53] Lei Wu,et al. Inflammation and tumor progression: signaling pathways and targeted intervention , 2021, Signal Transduction and Targeted Therapy.
[54] Sherine F. Elsawa,et al. Macrophage Polarization States in the Tumor Microenvironment , 2021, International journal of molecular sciences.
[55] Shaobing Zhou,et al. Correction to "Polarization of Tumor-Associated Macrophages by Nanoparticle Loaded Escherichia coli Combined with Immunogenic Cell Death for Cancer Immunotherapy". , 2021, Nano letters (Print).
[56] S. Feng,et al. Tumor-Associated-Macrophage-Membrane-Coated Nanoparticles for Improved Photodynamic Immunotherapy. , 2021, Nano letters.
[57] Duyang Gao,et al. Metabolizable Near-Infrared-II Nanoprobes for Dynamic Imaging of Deep-Seated Tumor-Associated Macrophages in Pancreatic Cancer. , 2021, ACS nano.
[58] Ming Jiang,et al. Developing a Novel Anticancer Gold(III) Agent to Integrate Chemotherapy and Immunotherapy. , 2021, Journal of medicinal chemistry.
[59] Shaobing Zhou,et al. Polarization of Tumor-Associated Macrophages by Nanoparticle-Loaded Escherichia coli Combined with Immunogenic Cell Death for Cancer Immunotherapy. , 2021, Nano letters.
[60] Mengying Hu,et al. mRNA Delivery of a Bispecific Single‐Domain Antibody to Polarize Tumor‐Associated Macrophages and Synergize Immunotherapy against Liver Malignancies , 2021, Advanced materials.
[61] A. Rauf,et al. Immunomodulation of Tumor Microenvironment by Arginine-Loaded Iron Oxide Nanoparticles for Gaseous Immunotherapy. , 2021, ACS applied materials & interfaces.
[62] Yinsong Wang,et al. Leukocyte/platelet hybrid membrane-camouflaged dendritic large pore mesoporous silica nanoparticles co-loaded with photo/chemotherapeutic agents for triple negative breast cancer combination treatment , 2021, Bioactive materials.
[63] G. Kwon,et al. Cell‐Based Delivery Systems: Emerging Carriers for Immunotherapy , 2021, Advanced Functional Materials.
[64] Jianguo Wang,et al. Targeting tumor-associated macrophages to synergize tumor immunotherapy , 2021, Signal Transduction and Targeted Therapy.
[65] Leaf Huang,et al. Tumor-targeted gene therapy with lipid nanoparticles inhibits tumor-associated adipocytes and remodels the immunosuppressive tumor microenvironment in triple-negative breast cancer. , 2021, Nanoscale horizons.
[66] B. Baradaran,et al. Immune Cell Membrane-Coated Biomimetic Nanoparticles for Targeted Cancer Therapy. , 2021, Small.
[67] Qi Chen,et al. Cyclodextrin-based host-guest complexes loaded with regorafenib for colorectal cancer treatment , 2021, Nature Communications.
[68] B. Zhu,et al. Metabolic regulatory crosstalk between tumor microenvironment and tumor-associated macrophages , 2021, Theranostics.
[69] Guifeng Zhang,et al. Tumor microenvironment remodeling and tumor therapy based on M2-like tumor associated macrophage-targeting nano-complexes , 2021, Theranostics.
[70] Xianqun Fan,et al. The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment , 2020, Bioactive materials.
[71] K. O'Byrne,et al. Understanding the tumor microenvironment for effective immunotherapy , 2020, Medicinal research reviews.
[72] Pingping Shen,et al. Targeting tumor-associated macrophages as an antitumor strategy. , 2020, Biochemical pharmacology.
[73] Ting Zhang,et al. Tumor-Associated Macrophages in Tumor Immunity , 2020, Frontiers in Immunology.
[74] Lin Zhu,et al. Targeting Tumor-Associated Macrophages by MMP2-Sensitive Apoptotic Body-Mimicking Nanoparticles. , 2020, ACS applied materials & interfaces.
[75] Xuesi Chen,et al. FXIIIa substrate peptide decorated BLZ945 nanoparticles for specifically remodeling tumor immunity. , 2020, Biomaterials science.
[76] H. Santos,et al. Peptide-guided resiquimod-loaded lignin nanoparticles convert tumor-associated macrophages from M2 to M1 phenotype for enhanced chemotherapy. , 2020, Acta biomaterialia.
[77] Anjali Sharma,et al. Targeted systemic dendrimer delivery of CSF‐1R inhibitor to tumor‐associated macrophages improves outcomes in orthotopic glioblastoma , 2020, Bioengineering & translational medicine.
[78] Mengyang Liu,et al. Targeted delivery of zoledronic acid through the sialic acid siglec axis for killing and reversal of M2 phenotypic tumor-associated macrophages - A promising cancer immunotherapy. , 2020, International journal of pharmaceutics.
[79] Jie Liu,et al. A targeting black phosphorus nanoparticle based immune cells nano-regulator for photodynamic/photothermal and photo-immunotherapy , 2020, Bioactive materials.
[80] Da-ke Li,et al. Characteristics and clinical trial results of agonistic anti-CD40 antibodies in the treatment of malignancies , 2020, Oncology letters.
[81] C. Peano,et al. Macrophage morphology correlates with single-cell diversity and prognosis in colorectal liver metastasis , 2020, The Journal of experimental medicine.
[82] W. Tap. ENLIVEN study: Pexidartinib for tenosynovial giant cell tumor (TGCT). , 2020, Future oncology.
[83] Kyung-Hyun Park-Min,et al. The M-CSF receptor in osteoclasts and beyond , 2020, Experimental & Molecular Medicine.
[84] Shuhui Li,et al. The double-edged sword effect of macrophage targeting delivery system in different macrophage subsets related diseases , 2020, Journal of Nanobiotechnology.
[85] Shen Gao,et al. Macrophage-cancer hybrid membrane-coated nanoparticles for targeting lung metastasis in breast cancer therapy , 2020, Journal of Nanobiotechnology.
[86] J. Rathmell,et al. Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy. , 2020, Molecular cell.
[87] D. D'Souza,et al. Bovine Milk Exosomes Affect Proliferation and Protect Macrophages against Cisplatin-Induced Cytotoxicity , 2020, Immunological investigations.
[88] T. Teesalu,et al. Targeting pro-tumoral macrophages in early primary and metastatic breast tumors with CD206-binding mUNO peptide. , 2020, Molecular pharmaceutics.
[89] Chuan Zhang,et al. Engineering macrophage-derived exosomes for targeted chemotherapy of triple-negative breast cancer. , 2020, Nanoscale.
[90] S. Mitragotri,et al. Cellular backpacks for macrophage immunotherapy , 2020, Science Advances.
[91] Mei-Rong Ke,et al. The Non-Covalent Indocyanine Green Conjugate of C-Phycocyanin: Preparation and Tumor-Associated Macrophages-Targeted Photothermal Therapeutics. , 2020, Bioconjugate chemistry.
[92] Quan Xia,et al. Paclitaxel-Loaded Macrophage Membrane Camouflaged Albumin Nanoparticles for Targeted Cancer Therapy , 2020, International journal of nanomedicine.
[93] J. Pollard,et al. Tumor-associated macrophages , 2020, Current Biology.
[94] Xinru Zhang,et al. Folate receptor-targeted RNAi nanoparticles for silencing STAT3 in tumor-associated macrophages and tumor cells. , 2020, Nanomedicine : nanotechnology, biology, and medicine.
[95] David M. Thomas,et al. Tumor-associated macrophages and macrophage-related immune checkpoint expression in sarcomas , 2020, Oncoimmunology.
[96] Zhong Luo,et al. Polarization of tumor-associated macrophage phenotype via porous hollow iron nanoparticles for tumor immunotherapy in vivo. , 2019, Nanoscale.
[97] S. Leong,et al. Abstract C087: Phase 1 study of DCC-3014, an oral inhibitor of CSF1R, to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with advanced solid tumors, including diffuse-type tenosynovial giant cell tumor , 2019 .
[98] M. Jücker,et al. PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer. , 2019, Biochemical pharmacology.
[99] Juan Ye,et al. Ginseng-derived nanoparticles alter macrophage polarization to inhibit melanoma growth , 2019, Journal of Immunotherapy for Cancer.
[100] Xinrong Liu,et al. Terminating the renewal of tumor-associated macrophages: a sialic acid-based targeted delivery strategy for cancer immunotherapy. , 2019, International journal of pharmaceutics.
[101] Hai‐Yan Xie,et al. Responsive exosome nano-bioconjugates for synergistic cancer therapy. , 2019, Angewandte Chemie.
[102] A. Kabanov,et al. Macrophage-Derived Extracellular Vesicles as Drug Delivery Systems for Triple Negative Breast Cancer (TNBC) Therapy , 2019, Journal of Neuroimmune Pharmacology.
[103] Yuchi Wang,et al. Target delivery selective CSF-1R inhibitor to tumor-associated macrophages via erythrocyte-cancer cell hybrid membrane camouflaged pH-responsive copolymer micelle for cancer immunotherapy. , 2019, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[104] M. Amiji,et al. Improved Anti-TumorEfficacy of Paclitaxel in Combination with MicroRNA-125b-based Tumor-Associated Macrophage Repolarization in Epithelial Ovarian Cancer. , 2019, Cancer letters.
[105] S. Ugel,et al. The Endless Saga of Monocyte Diversity , 2019, Front. Immunol..
[106] S. Choi,et al. Increased Antiangiogenic Effect by Blocking CCL2-dependent Macrophages in a Rodent Glioblastoma Model: Correlation Study with Dynamic Susceptibility Contrast Perfusion MRI , 2019, Scientific Reports.
[107] Mengyang Liu,et al. Targeted delivery of ibrutinib to tumor-associated macrophages by sialic acid-stearic acid conjugate modified nanocomplexes for cancer immunotherapy. , 2019, Acta biomaterialia.
[108] L. Galluzzi,et al. Macrophages and Metabolism in the Tumor Microenvironment. , 2019, Cell metabolism.
[109] H. Bae,et al. Targeting of M2-like tumor-associated macrophages with a melittin-based pro-apoptotic peptide , 2019, Journal of Immunotherapy for Cancer.
[110] Zhenzhong Zhang,et al. An in situ microenvironmental nano-regulator to inhibit the proliferation and metastasis of 4T1 tumor , 2019, Theranostics.
[111] R. Marasini,et al. Macrophage-derived exosome-mimetic hybrid vesicles for tumor targeted drug delivery. , 2019, Acta biomaterialia.
[112] Xiaofen Lu,et al. Depletion of tumor-associated macrophages enhances the anti-tumor effect of docetaxel in a murine epithelial ovarian cancer. , 2019, Immunobiology.
[113] J. Chen,et al. Pursuing Specific Chemotherapy of Orthotopic Breast Cancer with Lung Metastasis from Docking Nanoparticles Driven by Bioinspired Exosomes. , 2019, Nano letters.
[114] G. Getz,et al. Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39 , 2019, Nature Neuroscience.
[115] P. Spellman,et al. Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic Targets , 2019, Cancer cell.
[116] Y. Yeo,et al. Surface Modification of Polymeric Nanoparticles with M2pep Peptide for Drug Delivery to Tumor-Associated Macrophages , 2019, Pharmaceutical Research.
[117] Jun Feng,et al. Artificially Reprogrammed Macrophages as Tumor‐Tropic Immunosuppression‐Resistant Biologics to Realize Therapeutics Production and Immune Activation , 2019, Advanced materials.
[118] Wuli Yang,et al. Erythrocyte-cancer hybrid membrane-camouflaged melanin nanoparticles for enhancing photothermal therapy efficacy in tumors. , 2019, Biomaterials.
[119] Yongzhuo Huang,et al. Targeting lipid metabolism to overcome EMT-associated drug resistance via integrin β3/FAK pathway and tumor-associated macrophage repolarization using legumain-activatable delivery , 2019, Theranostics.
[120] Cui Tang,et al. Combination antitumor immunotherapy with VEGF and PIGF siRNA via systemic delivery of multi-functionalized nanoparticles to tumor-associated macrophages and breast cancer cells. , 2018, Biomaterials.
[121] Kristy M Ainslie,et al. A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1-insensitive models of triple-negative breast cancer. , 2018, JCI insight.
[122] D. Argyle,et al. Targeting Macrophage-Recruiting Chemokines as a Novel Therapeutic Strategy to Prevent the Progression of Solid Tumors , 2018, Front. Immunol..
[123] J. Pollard,et al. Targeting macrophages: therapeutic approaches in cancer , 2018, Nature Reviews Drug Discovery.
[124] C. A. Speck-Hernandez,et al. Paclitaxel Reduces Tumor Growth by Reprogramming Tumor-Associated Macrophages to an M1 Profile in a TLR4-Dependent Manner. , 2018, Cancer research.
[125] Yaping Li,et al. Bioengineered Macrophages Can Responsively Transform into Nanovesicles To Target Lung Metastasis. , 2018, Nano letters.
[126] Xiangrong Song,et al. Legumain, an asparaginyl endopeptidase, mediates the effect of M2 macrophages on attenuating renal interstitial fibrosis in obstructive nephropathy. , 2018, Kidney international.
[127] David J. Dowling. Recent Advances in the Discovery and Delivery of TLR7/8 Agonists as Vaccine Adjuvants , 2018, ImmunoHorizons.
[128] Haifeng Dong,et al. Erythrocyte-Cancer Hybrid Membrane Camouflaged Hollow Copper Sulfide Nanoparticles for Prolonged Circulation Life and Homotypic-Targeting Photothermal/Chemotherapy of Melanoma. , 2018, ACS nano.
[129] R. Sullivan,et al. Initial results from first-in-human study of IPI-549, a tumor macrophage-targeting agent, combined with nivolumab in advanced solid tumors. , 2018 .
[130] M. Amiji,et al. Repolarization of Tumor-Associated Macrophages in a Genetically Engineered Nonsmall Cell Lung Cancer Model by Intraperitoneal Administration of Hyaluronic Acid-Based Nanoparticles Encapsulating MicroRNA-125b. , 2018, Nano letters.
[131] R. Weinberg,et al. Understanding the tumor immune microenvironment (TIME) for effective therapy , 2018, Nature Medicine.
[132] Yifei Lu,et al. Macrophage-Membrane-Coated Nanoparticles for Tumor-Targeted Chemotherapy. , 2018, Nano letters.
[133] Weimin Yin,et al. Dual-targeting biomimetic delivery for anti-glioma activity via remodeling the tumor microenvironment and directing macrophage-mediated immunotherapy , 2018, Chemical science.
[134] Jing Qin,et al. Primary M1 macrophages as multifunctional carrier combined with PLGA nanoparticle delivering anticancer drug for efficient glioma therapy , 2018, Drug delivery.
[135] Yonghong Xu,et al. Harnessing the Cross-talk between Tumor Cells and Tumor-associated Macrophages with a Nano-drug for modulation of Glioblastoma Immune Microenvironment , 2017, bioRxiv.
[136] R. Zhuo,et al. A Dual Macrophage Targeting Nanovector for Delivery of Oligodeoxynucleotides To Overcome Cancer-Associated Immunosuppression. , 2017, ACS applied materials & interfaces.
[137] Q. Luo,et al. Molecular-Targeted Immunotherapeutic Strategy for Melanoma via Dual-Targeting Nanoparticles Delivering Small Interfering RNA to Tumor-Associated Macrophages. , 2017, ACS nano.
[138] H. Geng,et al. Reversing the polarization of tumor‐associated macrophages inhibits tumor metastasis , 2017, International immunopharmacology.
[139] Daniel G. Anderson,et al. Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy , 2017, The Journal of clinical investigation.
[140] Q. Lei,et al. Mannosylated liposomes improve therapeutic effects of paclitaxel in colon cancer models , 2017, Journal of microencapsulation.
[141] C. Ries,et al. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy , 2017, Journal of Immunotherapy for Cancer.
[142] Melissa L. Johnson,et al. A phase 1b/2 study of ARRY-382, an oral inhibitor of colony stimulating factor 1 receptor (CSF1R), in combination with pembrolizumab (Pembro) for the treatment of patients (Pts) with advanced solid tumors. , 2017 .
[143] M. K. Chourasia,et al. Targeting tumor associated macrophages (TAMs) via nanocarriers , 2017, Journal of controlled release : official journal of the Controlled Release Society.
[144] Song Shen,et al. Spatial Targeting of Tumor-Associated Macrophages and Tumor Cells with a pH-Sensitive Cluster Nanocarrier for Cancer Chemoimmunotherapy. , 2017, Nano letters.
[145] H. Bae,et al. Melittin suppresses tumor progression by regulating tumor-associated macrophages in a Lewis lung carcinoma mouse model , 2017, Oncotarget.
[146] Ronnie H. Fang,et al. Erythrocyte–Platelet Hybrid Membrane Coating for Enhanced Nanoparticle Functionalization , 2017, Advanced materials.
[147] Alberto Mantovani,et al. Tumour-associated macrophages as treatment targets in oncology , 2017, Nature Reviews Clinical Oncology.
[148] M. Merchant,et al. SDF-1 Blockade Enhances Anti-VEGF Therapy of Glioblastoma and Can Be Monitored by MRI , 2016, Neoplasia.
[149] C. Lo,et al. Tumor Microenvironment-Responsive Nanoparticle Delivery of Chemotherapy for Enhanced Selective Cellular Uptake and Transportation within Tumor. , 2016, Biomacromolecules.
[150] Morteza Mahmoudi,et al. Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues. , 2016, Nature nanotechnology.
[151] Philippe Foubert,et al. PI3Kγ is a molecular switch that controls immune suppression , 2016, Nature.
[152] Haijun Yu,et al. Liposomes Coated with Isolated Macrophage Membrane Can Target Lung Metastasis of Breast Cancer. , 2016, ACS nano.
[153] Kathryn J Fowler,et al. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. , 2016, The Lancet. Oncology.
[154] R. Jain,et al. Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages , 2016, Proceedings of the National Academy of Sciences.
[155] D. Ribatti,et al. A novel liposomal Clodronate depletes tumor-associated macrophages in primary and metastatic melanoma: Anti-angiogenic and anti-tumor effects. , 2016, Journal of controlled release : official journal of the Controlled Release Society.
[156] Ting Liu,et al. Bioconjugated Manganese Dioxide Nanoparticles Enhance Chemotherapy Response by Priming Tumor-Associated Macrophages toward M1-like Phenotype and Attenuating Tumor Hypoxia. , 2016, ACS nano.
[157] Jing-quan Li,et al. Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma , 2015, Gut.
[158] Zahi A. Fayad,et al. PET Imaging of Tumor-Associated Macrophages with 89Zr-Labeled High-Density Lipoprotein Nanoparticles , 2015, The Journal of Nuclear Medicine.
[159] H. Byrne,et al. Dual Targeted Immunotherapy via In Vivo Delivery of Biohybrid RNAi‐Peptide Nanoparticles to Tumor‐Associated Macrophages and Cancer Cells , 2015, Advanced functional materials.
[160] E. Yonemochi,et al. Zoledronic acid enhances antitumor efficacy of liposomal doxorubicin. , 2015, International journal of oncology.
[161] R. Markwald,et al. Interactions between Hyaluronan and Its Receptors (CD44, RHAMM) Regulate the Activities of Inflammation and Cancer , 2015, Front. Immunol..
[162] J. Tabernero,et al. Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study , 2015, Targeted Oncology.
[163] P. Roche,et al. Macropinocytosis in phagocytes: regulation of MHC class-II-restricted antigen presentation in dendritic cells , 2015, Front. Physiol..
[164] R. Carrio,et al. Paracrine Interactions between Adipocytes and Tumor Cells Recruit and Modify Macrophages to the Mammary Tumor Microenvironment: The Role of Obesity and Inflammation in Breast Adipose Tissue , 2015, Cancers.
[165] Xiaogang Qu,et al. Immunostimulatory oligonucleotides-loaded cationic graphene oxide with photothermally enhanced immunogenicity for photothermal/immune cancer therapy. , 2014, Biomaterials.
[166] K. Mertz,et al. Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis , 2014, Nature.
[167] Youssef W. Naguib,et al. Biodistribution and in Vivo Activities of Tumor-Associated Macrophage-Targeting Nanoparticles Incorporated with Doxorubicin , 2014, Molecular pharmaceutics.
[168] Will Liao,et al. The cellular and molecular origin of tumor-associated macrophages , 2014, Science.
[169] L. Coussens,et al. CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8+ T cells , 2013, Oncoimmunology.
[170] Lu Zhang,et al. Intravenous delivery of siRNA targeting CD47 effectively inhibits melanoma tumor growth and lung metastasis. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.
[171] S. Pun,et al. Targeted delivery of proapoptotic peptides to tumor-associated macrophages improves survival , 2013, Proceedings of the National Academy of Sciences.
[172] Jaesung Park,et al. Bioinspired exosome-mimetic nanovesicles for targeted delivery of chemotherapeutics to malignant tumors. , 2013, ACS nano.
[173] Z. Cui,et al. Targeting of tumor-associated macrophages made possible by PEG-sheddable, mannose-modified nanoparticles. , 2013, Molecular pharmaceutics.
[174] P. Allavena,et al. Tumor-associated macrophages: functional diversity, clinical significance, and open questions , 2013, Seminars in Immunopathology.
[175] R. Shao. YKL-40 acts as an angiogenic factor to promote tumor angiogenesis , 2013, Front. Physiol..
[176] M. Zucchetti,et al. Role of macrophage targeting in the antitumor activity of trabectedin. , 2013, Cancer cell.
[177] A. Tolcher,et al. A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors , 2013, Cancer Chemotherapy and Pharmacology.
[178] Hengyi Xiao,et al. Anti‐tumour strategies aiming to target tumour‐associated macrophages , 2013, Immunology.
[179] Lauren A Austin,et al. Small molecule-gold nanorod conjugates selectively target and induce macrophage cytotoxicity towards breast cancer cells. , 2012, Small.
[180] B. Badie,et al. Intracerebral CpG Immunotherapy with Carbon Nanotubes Abrogates Growth of Subcutaneous Melanomas in Mice , 2012, Clinical Cancer Research.
[181] Tej B. Shrestha,et al. Magnetic-Fe/Fe3O4-nanoparticle-bound SN38 as carboxylesterase-cleavable prodrug for the delivery to tumors within monocytes/macrophages , 2012, Beilstein journal of nanotechnology.
[182] S. Adams,et al. Phase I/II study of resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with melanoma. , 2012 .
[183] S. Natsugoe,et al. Clinical Significance of Folate Receptor β–expressing Tumor-associated Macrophages in Pancreatic Cancer , 2012, Annals of Surgical Oncology.
[184] Wu Sun,et al. Role of TLR4 and TCR or BCR against baicalin-induced responses in T and B cells. , 2011, International immunopharmacology.
[185] I. Holen,et al. Tumour macrophages as potential targets of bisphosphonates , 2011, Journal of Translational Medicine.
[186] D. Zopf,et al. Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity , 2011, International journal of cancer.
[187] Samir Mitragotri,et al. Cell‐Based Drug Delivery Devices Using Phagocytosis‐Resistant Backpacks , 2011, Advanced materials.
[188] S. Osinsky,et al. Hypoxia, tumour-associated macrophages, microvessel density, VEGF and matrix metalloproteinases in human gastric cancer: interaction and impact on survival , 2011, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.
[189] K. Shirouzu,et al. Infiltration of thymidine phosphorylase-positive macrophages is closely associated with tumor angiogenesis and survival in intestinal type gastric cancer. , 2010, Oncology reports.
[190] Jeffrey W. Pollard,et al. Macrophage Diversity Enhances Tumor Progression and Metastasis , 2010, Cell.
[191] A. Ullrich,et al. Paul Ehrlich's magic bullet concept: 100 years of progress , 2008, Nature Reviews Cancer.
[192] I. Fidler,et al. Stromal metalloproteinase-9 is essential to angiogenesis and progressive growth of orthotopic human pancreatic cancer in parabiont nude mice. , 2007, Neoplasia.
[193] L. Coussens,et al. Inflammation and cancer , 2002, Nature.
[194] H. Saji,et al. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[195] OUP accepted manuscript , 2022, Nucleic Acids Research.
[196] Michael F. Cuccarese,et al. TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy. , 2018, Nature biomedical engineering.
[197] Hongda Wang,et al. Red blood cell-derived nanovesicles for safe and efficient macrophage-targeted drug delivery in vivo. , 2018, Biomaterials science.
[198] A. Jose,et al. Effective Skin Cancer Treatment by Topical Co-delivery of Curcumin and STAT3 siRNA Using Cationic Liposomes , 2017, AAPS PharmSciTech.
[199] Naveid A Ali,et al. Real-time intravital imaging establishes tumor-associated macrophages as the extraskeletal target of bisphosphonate action in cancer. , 2015, Cancer discovery.
[200] H. Gerber,et al. Targeting inflammatory cells to improve anti-VEGF therapies in oncology. , 2010, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[201] R. Horuk,et al. Chemokine receptor antagonists: overcoming developmental hurdles , 2009, Nature Reviews Drug Discovery.
[202] W. A. Yeudall,et al. Dovepress Open Access to Scientific and Medical Research Open Access Full Text Article Surface Engineering of Macrophages with Nanoparticles to Generate a Cell–nanoparticle Hybrid Vehicle for Hypoxia-targeted Drug Delivery , 2022 .